Aclaris Therapts (ACRS) Stock Price, Quote & News

Company Profile

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 324 7933

Website: www.aclaristx.com

Address:

701 Lee Road, Suite 103, Wayne, United States

OriginalTradeonrumor May. 21 at 2:10 AM

$ACRS keep an eye on close above 4.60 then we are off to the races!!? Let’s see what happens!!

0 · Reply

OriginalTradeonrumor May. 20 at 8:19 PM

$ACRS as promised 🥳…unless overall market tanks tommorow we should challenge 4.60’s

0 · Reply

OriginalTradeonrumor May. 20 at 8:11 PM

$ACRS well I guess we finished great!!!

0 · Reply

OriginalTradeonrumor May. 20 at 7:28 PM

$ACRS close over 4.50 would be great!!!!🙏 …

0 · Reply

OriginalTradeonrumor May. 20 at 3:55 PM

$ACRS interesting trading today…counter XBI recovery …I have to think that this is getting ready for a big move up and they are clearing the decks…..don’t get shaken out where we are at now 4.40….odds are we’ll be higher at close Let’s see what happens!

0 · Reply

OriginalTradeonrumor May. 20 at 3:53 PM

$ACRS Ai all the way 🤣

0 · Reply

NVDAMillionaire May. 19 at 9:49 PM

$ACRS Really good write-up that perfectly summarizes ACRS's present situation. So if you want to bring your ACRS knowledge up to date or just discover ACRS, this is required reading. https://everyticker.com/quote/ACRS/analysis/aclaris-therapeutics-a-capital-efficient-pipeline-bet-in-the-jak-wars-nasdaq-acrs

0 · Reply

gATERaids May. 19 at 4:10 PM

$ACRS Up over 200% since he posted this FUD $ATER

1 · Reply

OriginalTradeonrumor May. 19 at 5:32 AM

$ACRS that’s what happened 🤣🥳

0 · Reply

OriginalTradeonrumor May. 18 at 5:45 PM

$ACRS Let’s see what happens!

0 · Reply

Aclaris Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

May 14, 2026, 12:35 PM EDT - 6 days ago

Aclaris Therapeutics Slides: FY 2026

May 8, 2026, 8:30 AM EDT - 12 days ago

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

2026-05-07T15:19:50.000Z - 13 days ago

Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c)

2026-05-07T13:36:55.000Z - 13 days ago

Aclaris Therapeutics reports Q1 EPS (15c), consensus (16c)

May 7, 2026, 7:00 AM EDT - 13 days ago

Aclaris Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 13 days ago

Aclaris Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 13 days ago

Aclaris Therapeutics Slides: Corporate presentation

May 7, 2026, 6:59 AM EDT - 13 days ago

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

2026-05-05T10:58:43.000Z - 15 days ago

Aclaris Therapeutics price target raised to $11 from $7 at Piper Sandler

2026-05-05T08:30:14.000Z - 15 days ago

Aclaris Therapeutics initiated with a Buy at Guggenheim

2026-05-04T20:40:03.000Z - 16 days ago

Aclaris Therapeutics initiated with a Buy at Guggenheim

2026-04-29T12:21:19.000Z - 21 days ago

Aclaris Therapeutics price target raised to $10 from $8 at Wedbush

Apr 28, 2026, 8:30 AM EDT - 22 days ago

Aclaris Therapeutics Transcript: Study update

Apr 28, 2026, 8:30 AM EDT - 22 days ago

Aclaris Therapeutics Press release: Study update

Apr 28, 2026, 8:30 AM EDT - 22 days ago

Aclaris Therapeutics Slides: Study update

2026-04-28T11:21:27.000Z - 22 days ago

Aclaris Therapeutics’ ATI-052 antibody shows PK efficacy in Phase 1a trial

Apr 28, 2026, 6:30 AM EDT - 22 days ago

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

Apr 27, 2026, 4:45 PM EDT - 23 days ago

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

2026-04-27T15:45:50.000Z - 23 days ago

Aclaris Therapeutics management to meet virtually with Craig-Hallum

Apr 23, 2026, 8:00 AM EDT - 27 days ago

Aclaris Therapeutics Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 27 days ago

Aclaris Therapeutics Proxy statement: Proxy filing

2026-04-16T11:01:43.000Z - 4 weeks ago

Aclaris Therapeutics initiated with an Outperform at Oppenheimer

Apr 14, 2026, 12:00 PM EDT - 5 weeks ago

Aclaris Therapeutics Transcript: H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Apr 8, 2026, 8:30 AM EDT - 6 weeks ago

Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Mar 27, 2026, 10:10 AM EDT - 7 weeks ago

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

Mar 20, 2026, 11:00 AM EDT - 2 months ago

Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

2026-03-18T11:18:06.000Z - 2 months ago

Aclaris Therapeutics completes patient enrollment in Phase 2 trial of bosakitug

Mar 18, 2026, 6:55 AM EDT - 2 months ago

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

2026-03-12T11:46:37.000Z - 2 months ago

Helus Pharma appoints Conwell as Chief People Officer

HELP

Mar 10, 2026, 1:40 PM EDT - 2 months ago

Aclaris Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Feb 26, 2026, 8:40 AM EST - 2 months ago

Aclaris Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-02-26T12:39:16.000Z - 2 months ago

Aclaris Therapeutics reports Q4 EPS (16c), consensus (14c)

2026-02-26T12:30:02.000Z - 2 months ago

Aclaris Therapeutics reports Q4 EPS (16c), consensus (14c)

Feb 26, 2026, 7:00 AM EST - 2 months ago

Aclaris Therapeutics Annual report: Q4 2025

Feb 26, 2026, 7:00 AM EST - 2 months ago

Aclaris Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 6:58 AM EST - 2 months ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

2026-02-24T12:26:58.000Z - 3 months ago

Aclaris Therapeutics initiates Phase 1b PoC trial of ATI-052

Feb 24, 2026, 7:00 AM EST - 3 months ago

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052

Feb 12, 2026, 2:30 PM EST - 3 months ago

Aclaris Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

2026-01-30T12:11:21.000Z - 3 months ago

Aclaris Therapeutics initiated with a Buy at Craig-Hallum

2026-01-30T12:10:17.000Z - 3 months ago

Craig-Hallum bullish on Aclaris Therapeutics, initiates with a Buy

2026-01-27T12:01:40.000Z - 4 months ago

Aclaris Therapeutics reports ‘positive’ results from ATI-2138

Jan 27, 2026, 6:55 AM EST - 4 months ago

Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)

2026-01-12T12:44:41.000Z - 4 months ago

Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052

Jan 12, 2026, 6:55 AM EST - 4 months ago

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052

Jan 6, 2026, 8:00 AM EST - 4 months ago

Aclaris Therapeutics Transcript: Study Result

Jan 6, 2026, 8:00 AM EST - 4 months ago

Aclaris Therapeutics Press release: Study Result

Jan 6, 2026, 8:00 AM EST - 4 months ago

Aclaris Therapeutics Slides: Study Result

Jan 6, 2026, 6:59 AM EST - 4 months ago

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

Dec 19, 2025, 4:01 PM EST - 5 months ago

Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)

Dec 2, 2025, 11:00 AM EST - 6 months ago

Aclaris Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 6 months ago

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 17, 2025, 9:00 AM EST - 6 months ago

Aclaris Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 1:20 PM EST - 6 months ago

Aclaris Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 11:00 AM EST - 6 months ago

Aclaris Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 9, 2025, 6:00 PM EST - 6 months ago

Aclaris Therapeutics Slides: Corporate Presentation

Nov 6, 2025, 7:00 AM EST - 6 months ago

Aclaris Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 6 months ago

Aclaris Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 6:59 AM EST - 6 months ago

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 29, 2025, 7:30 AM EDT - 7 months ago

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

Oct 14, 2025, 8:00 AM EDT - 7 months ago

Aclaris Therapeutics Transcript: R&D Day 2025

Oct 14, 2025, 8:00 AM EDT - 7 months ago

Aclaris Therapeutics Slides: FY 2025

Sep 30, 2025, 7:00 AM EDT - 8 months ago

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

Sep 9, 2025, 9:00 AM EDT - 9 months ago

Aclaris Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 7:00 AM EDT - 9 months ago

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress

Sep 3, 2025, 1:00 PM EDT - 9 months ago

Aclaris Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 27, 2025, 8:00 AM EDT - 9 months ago

Aclaris Therapeutics to Participate in Two September Healthcare Conferences

Aug 7, 2025, 7:00 AM EDT - 10 months ago

Aclaris Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 10 months ago

Aclaris Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 6:59 AM EDT - 10 months ago

Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 29, 2025, 5:00 PM EDT - 10 months ago

Aclaris Therapeutics Transcript: Status Update

Jul 29, 2025, 5:00 PM EDT - 10 months ago

Aclaris Therapeutics Press release: Status Update

Jul 29, 2025, 5:00 PM EDT - 10 months ago

Aclaris Therapeutics Slides: Status Update

Jul 29, 2025, 4:01 PM EDT - 10 months ago

Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints

Jul 28, 2025, 8:45 AM EDT - 10 months ago

Aclaris Therapeutics Announces Leadership Transition

Jun 30, 2025, 11:30 AM EDT - 11 months ago

Aclaris Therapeutics Transcript: HCW Annual Inflammation & Immunology Virtual Conference 2025

Jun 30, 2025, 11:30 AM EDT - 11 months ago

Aclaris Therapeutics Slides: FY 2025

Jun 30, 2025, 9:31 AM EDT - 11 months ago

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

Jun 26, 2025, 4:01 PM EDT - 11 months ago

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

Jun 23, 2025, 6:59 AM EDT - 11 months ago

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

Jun 11, 2025, 1:20 PM EDT - 1 year ago

Aclaris Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 10:30 AM EDT - 1 year ago

Aclaris Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 9:20 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

May 9, 2025, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

May 8, 2025, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Earnings release: Q1 2025

May 8, 2025, 6:50 AM EDT - 1 year ago

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 29, 2025, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Aclaris Therapeutics Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Aclaris Therapeutics Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Aclaris Therapeutics Proxy statement: Proxy Filing

Mar 27, 2025, 9:00 AM EDT - 1 year ago

Aclaris Therapeutics Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 11, 2025, 3:00 PM EDT - 1 year ago

Aclaris Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 4, 2025, 7:00 AM EST - 1 year ago

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

Feb 27, 2025, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Annual report: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Registration statement: Registration Filing

Feb 12, 2025, 6:50 AM EST - 1 year ago

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Jan 30, 2025, 4:01 PM EST - 1 year ago

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Jan 6, 2025, 4:30 PM EST - 1 year ago

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dec 19, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Registration statement: Registration Filing

Dec 3, 2024, 1:00 PM EST - 1 year ago

Aclaris Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 4:30 PM EST - 1 year ago

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 18, 2024, 8:50 AM EST - 1 year ago

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Nov 18, 2024, 8:30 AM EST - 1 year ago

Aclaris Therapeutics Transcript: Status Update

Nov 18, 2024, 8:30 AM EST - 1 year ago

Aclaris Therapeutics Press release: Status Update

Nov 18, 2024, 8:30 AM EST - 1 year ago

Aclaris Therapeutics Slides: Status Update

Nov 18, 2024, 8:10 AM EST - 1 year ago

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Nov 18, 2024, 8:10 AM EST - 1 year ago

Aclaris Therapeutics Announces $80 Million Private Placement

Nov 6, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Quarterly report: Q3 2024

Nov 6, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Earnings release: Q3 2024

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Aclaris Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Sep 10, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Quarterly report: Q2 2024

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Earnings release: Q2 2024

Jul 16, 2024, 4:01 PM EDT - 2 years ago

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Jul 11, 2024, 7:12 AM EDT - 2 years ago

3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices

CRSP OTLK

Jun 25, 2024, 12:36 PM EDT - 2 years ago

Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)

Jun 11, 2024, 11:20 AM EDT - 2 years ago

Aclaris Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 6, 2024, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 8, 2024, 6:30 AM EDT - 2 years ago

American Clinical Research Services Announces Strategic Acquisition of Elixia

May 7, 2024, 5:00 PM EDT - 2 years ago

Aclaris Therapeutics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

Aclaris Therapeutics Quarterly report: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

Aclaris Therapeutics Earnings release: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

Aclaris Therapeutics Slides: Q1 2024

May 7, 2024, 4:01 PM EDT - 2 years ago

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Aclaris Therapeutics Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Aclaris Therapeutics Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Feb 27, 2024, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Feb 27, 2024, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Annual report: Q4 2023

Feb 27, 2024, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Earnings release: Q4 2023

Jan 10, 2024, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Dec 19, 2023, 4:01 PM EST - 2 years ago

Aclaris Therapeutics Provides Corporate Update

OriginalTradeonrumor May. 21 at 2:10 AM

$ACRS keep an eye on close above 4.60 then we are off to the races!!? Let’s see what happens!!

0 · Reply

OriginalTradeonrumor May. 20 at 8:19 PM

$ACRS as promised 🥳…unless overall market tanks tommorow we should challenge 4.60’s

0 · Reply

OriginalTradeonrumor May. 20 at 8:11 PM

$ACRS well I guess we finished great!!!

0 · Reply

OriginalTradeonrumor May. 20 at 7:28 PM

$ACRS close over 4.50 would be great!!!!🙏 …

0 · Reply

OriginalTradeonrumor May. 20 at 3:55 PM

0 · Reply

OriginalTradeonrumor May. 20 at 3:53 PM

$ACRS Ai all the way 🤣

0 · Reply

NVDAMillionaire May. 19 at 9:49 PM

0 · Reply

gATERaids May. 19 at 4:10 PM

$ACRS Up over 200% since he posted this FUD $ATER

1 · Reply

OriginalTradeonrumor May. 19 at 5:32 AM

$ACRS that’s what happened 🤣🥳

0 · Reply

OriginalTradeonrumor May. 18 at 5:45 PM

$ACRS Let’s see what happens!

0 · Reply

OriginalTradeonrumor May. 18 at 4:17 PM

$ACRS current daily

0 · Reply

OriginalTradeonrumor May. 18 at 4:16 PM

$ACRS XBI at a pretty solid floor now (127-128)…hoping it stabilizes as then so will $ACRS ….not giving it much hope today but I am keeping an eye on daily mid Bolingeras that’s out only hope to stop the bleed today 🙏🙂

0 · Reply

OriginalTradeonrumor May. 18 at 2:16 PM

$ACRS another walk down this time on anemic volume…I’ve been buying on the way down in .10 increments ….must bought more in the “.35’s”…if we go into the 4.20’s I’ll be buying again ….rinse and repeat 😁 Let’s see what happens!

0 · Reply

GreenEnergy1 May. 18 at 2:13 AM

$ACRS $6.50 by June 1st, but a lot of volatility on thw way. Very likely to see $10 by year end.

0 · Reply

seanolbrych May. 17 at 9:00 AM

$ACRS how high can this stock go?

0 · Reply

Vladxccc May. 15 at 8:45 PM

$ACRS Another red day and im selling

0 · Reply

Acan1219 May. 15 at 7:51 PM

$ACRS This is why! Shorts!!

0 · Reply

Acan1219 May. 15 at 7:48 PM

$ACRS Are you in??

1 · Reply

Vladxccc May. 15 at 7:47 PM

$ACRS 🩸

0 · Reply

Vladxccc May. 14 at 2:44 PM

$ACRS 💀🫪

0 · Reply

Acan1219 May. 14 at 12:55 AM

$ACRS Latest Overnight Price is Looking Spicy my Bull’s! Double Digits incoming! Imho..

0 · Reply

Acan1219 May. 13 at 8:58 PM

$ACRS Nope! Check those Charts again! Much Higher!

0 · Reply

Market Cap	621.51M
Revenue (ttm)	7.83M
Net Income (ttm)	-64.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-829.12%
Debt to Equity Ratio	0.00

Volume	993,000
Avg Vol	1,499,564
Day's Range	N/A - N/A
Shares Out	139.66M
Stochastic %K	33%
Beta	0.76
Analysts	Strong Sell
Price Target	$9.67